Article
Oncology
Giuseppe Minniti, Gaetano Lanzetta, Luca Capone, Martina Giraffa, Ivana Russo, Francesco Cicone, Alessandro Bozzao, Filippo Alongi, Luca Nicosia, Gioia Fineschi, Luca Marchetti, Tommaso Tufo, Federico Bianciardi, Vincenzo Esposito, PierCarlo Gentile, Sergio Paolini
Summary: The study evaluated the effects of postoperative stereotactic radiosurgery (SRS) with immunotherapy compared to SRS alone in patients with resected brain metastases (BM). The combination therapy showed a lower rate of leptomeningeal disease (LMD) and distant brain parenchymal failure (DBF), leading to reduced neurological death and prolonged survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Christopher Cultrara, Christopher Uhl, Kenneth Kirby, Essam Abed Elrazaq, Amelia Zellander, David W. Andrews, Charles B. Scott, Lorenzo Galluzzi, Mark A. Exley, Jenny Zilberberg
Summary: IGV-001 is a personalized, autologous cancer cell-based immunotherapy that delivers a tumor-derived antigenic payload with immunostimulatory signals for the treatment of glioblastoma (GBM) patients. It has shown promising clinical activity and safety in newly diagnosed GBM patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Tessa Gargett, Lisa M. Ebert, Nga T. H. Truong, Paris M. Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C. F. Yeo, Nicole L. Wittwer, Briony L. Gliddon, Melinda N. Tea, Rebecca Ormsby, Santosh Poonnoose, Jake Nowicki, Orazio Vittorio, David S. Ziegler, Stuart M. Pitson, Michael P. Brown
Summary: Targeting the tumor-associated antigen GD2 using CAR-T-cell therapy has shown promising results in controlling tumor growth in primary glioblastoma. Highly functional GD2-specific CAR-T cells can be produced using an approved clinical manufacturing process. The use of markers identified in the study has further improved tumor control rates.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Zhenghao Wu, Zihan Xi, Yunxiao Xiao, Xiangwang Zhao, Jiexiao Li, Nan Feng, Longqing Hu, Renjing Zheng, Ning Zhang, Shuntao Wang, Tao Huang
Summary: This study examines the role of thyroid-stimulating hormone (TSH) in tumor immunity. It finds that TSH promotes tumor growth and invasion in thyroid cancers and glioma through the TSH receptor (TSHR) pathway. TSH also induces the expression of programmed death-ligand 1 (PD-L1) in tumors, contributing to immune evasion. Inhibiting TSHR reverses tumor immune evasion and enhances T effector cell activation. These findings suggest that TSH suppression therapy could be an effective strategy in combination with immune checkpoint blockades.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Nan Qin, Lena Bluemel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Allison Cole, Joselyn Cruz-Cruz, Claus M. Graef, Matthias Woelfl, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stuehler, Stephen T. Keir, Darell D. Bigner, Julia Hauer, Thomas Beez, Christiane B. Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K. Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H. Cheshier, Guido Reifenberger, Arndt Borkhardt, Thomas Kurz, Marc Remke, Siddhartha Mitra
Summary: In this study, the researchers discovered that the inhibitor CI-994, which targets epigenetic modifiers, has significant therapeutic effects on MYC-driven medulloblastoma. By modulating the CD47-SIRP alpha phagocytosis checkpoint pathway and enhancing macrophage phagocytosis, CI-994 provides a new strategy to enhance cancer immunotherapy responses.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jessica B. Foster, Crystal Griffin, Jo Lynne Rokita, Allison Stern, Cameron Brimley, Komal Rathi, Maria Lane, Samantha N. Buongervino, Tiffany Smith, Peter J. Madsen, Daniel Martinez, Alberto Delaidelli, Poul H. Sorensen, Robert J. Wechsler-Reya, Katalin Kariko, Phillip B. Storm, David M. Barrett, Adam C. Resnick, John M. Maris, Kristopher R. Bosse
Summary: This study identified high GPC2 expression in pediatric brain tumors and developed an mRNA CAR T cell approach targeting GPC2, showing significant GPC2-specific cell death and tumor regression without toxicity. These findings lay the foundation for clinical translation of GPC2-directed immunotherapies for pediatric brain tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Tereza Andreou, Jennifer Williams, Rebecca J. Brownlie, Robert J. Salmond, Erica Watson, Gary Shaw, Alan Melcher, Heiko Wurdak, Susan C. Short, Mihaela Lorger
Summary: The study focuses on using hematopoietic stem cell (HSC) gene therapy to target tumor-infiltrating myeloid cells in glioblastoma (GBM), achieving specific gene delivery through a lentiviral vector, blocking TGFβ in combination with radiotherapy significantly reduced tumor burden and prolonged survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Daniel Kalinovsky, Alexey Kibardin, Irina Kholodenko, Elena Svirshchevskaya, Igor I. Doronin, Mariya Konovalova, Maria Grechikhina, Fedor N. Rozov, Sergey S. Larin, Sergey M. Deyev, Roman Kholodenko
Summary: This study is the first to analyze the cytotoxic activity of anti-GD2 antibody-drug conjugates (ADCs) against solid tumors. The ADCs showed cytotoxic effects in a wide panel of GD2-positive tumor cell lines and demonstrated antitumor effects in mouse models of GD2-positive solid cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Takayuki Ohkuri, Akemi Kosaka, Maki Ikeura, Andres M. Salazar, Hideho Okada
Summary: While adoptive transfer of T-cells has been successful for B cell malignancies, developing effective T-cell-based immunotherapy for CNS tumors like glioblastoma remains challenging. Tc17-1 cells, which produce both IL-17 and IFN-gamma, showed promising results in combination with poly-ICLC and peptide vaccine treatment in a preclinical GBM model.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ana Cloquell, Isidro Mateo, Stefano Gambera, Marti Pumarola, Ramon Alemany, Javier Garcia-Castro, Ana Judith Perise-Barrios
Summary: This study demonstrates that dCelyvir is safe and effective in canine rostrotentorial high-grade gliomas. ICOCAV17 was detected in peripheral blood in nine dogs, and a correlation between the ICOCAV17 particles and anti-canine adenovirus (CAV) antibodies was observed. ICOCAV17 was detected in 3/9 tumor tissues after necropsies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Landon C. Brown, Kunal Desai, Wei Wei, Emily N. Kinsey, Chester Kao, Daniel J. George, Brian Rini, Moshe C. Ornstein, Tian Zhang
Summary: This study retrospectively evaluated the outcomes of intermediate or poor-risk untreated metastatic renal cell carcinoma patients with brain metastasis treated with ipilimumab plus nivolumab. The results indicated that the combination therapy, along with CNS-directed local therapy, showed clinical efficacy in patients with mRCC and brain metastasis, with responses seen beyond the first-line setting. Further investigation is warranted in this population due to exclusion from prior clinical trials.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Jun Ye, Yue Gao, Ming Ji, Yanfang Yang, Zhaohui Wang, Baolian Wang, Jing Jin, Ling Li, Hongliang Wang, Xiaoyan Xu, Hengfeng Liao, Chunfang Lian, Yaqi Xu, Renjie Li, Tong Sun, Lili Gao, Yan Li, Xiaoguang Chen, Yuling Liu
Summary: This study developed a self-microemulsifying drug delivery system carrying chlorogenic acid, successfully delivering immunomodulators to mesenteric lymph nodes efficiently. Through promoting immune cell activity and inhibiting immunosuppressive factors, it achieved significant antitumor effects in inhibiting tumor growth.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Maximilian O. Schaettler, Rupen Desai, Anthony Z. Wang, Alexandra J. Livingstone, Dale K. Kobayashi, Andrew T. Coxon, Jay A. Bowman-Kirigin, Connor J. Liu, Mao Li, Diane E. Bender, Michael J. White, David M. Kranz, Tanner M. Johanns, Gavin P. Dunn
Summary: Researchers isolated a TCR specific for the Imp3(D81N) neoantigen and generated the MISTIC mouse model. Adoptive cellular therapy using MISTIC T cells showed potential therapeutic efficacy for glioblastoma treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Mohammed G. Ghonime, Uksha Saini, Michael C. Kelly, Justin C. Roth, Pin-Yi Wang, Chun-Yu Chen, Katherine Miller, Ilse Hernandez-Aguirre, Yeaseul Kim, Xiaokui Mo, Joseph R. Stanek, Tim Cripe, Elaine Mardis, Kevin A. Cassady
Summary: The study developed a multimodal oncolytic herpes simplex virus expressing EphA2 tumor-associated antigen, which induced robust antitumor immune responses in murine brain and peripheral tumor models, enhancing survival in viroimmunotherapy resistant tumors and producing EphA2-specific CD8 effector-like T-cell populations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Erin F. Simonds, Edbert D. Lu, Oscar Badillo, Shokoufeh Karimi, Eric Liu, Whitney Tamaki, Chiara Rancan, Kira M. Downey, Jacob Stultz, Meenal Sinha, Lauren K. McHenry, Nicole M. Nasholm, Pavlina Chuntova, Anders Sundstrom, Vassilis Genoud, Shilpa A. Shahani, Leo D. Wang, Christine E. Brown, Paul R. Walker, Fredrik J. Swartling, Lawrence Fong, Hideho Okada, William A. Weiss, Mats Hellstrom
Summary: This study compared the tumor immune microenvironments of ICI-responsive and ICI-refractory tumors, identifying T cells and dendritic cells as key factors associated with ICI sensitivity. Mouse models suggested that poor antigen presentation in the brain may contribute to ICI resistance in GBM. Rational immunotherapeutic combinations targeting DCs and PD-L1+ tumor-associated macrophages showed promising results in vivo.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Clinical Neurology
Paul-Adrian Calburean, Luigi Pannone, Antonio Sorgente, Anais Gauthey, Cinzia Monaco, Antanas Strazdas, Alexandre Almorad, Antonio Bisignani, Gezim Bala, Robbert Ramak, Ingrid Overeinder, Erwin Stroker, Gudrun Pappaert, Sonia Van Dooren, Thomy de Ravel, Mark La Meir, Pedro Brugada, Juan Sieira, Gian-Battista Chierchia, Carlo de Asmundis
Summary: This study evaluated changes in electrocardiographic parameters during ajmaline testing for the diagnosis of Brugada syndrome (BrS). The results showed that important heart rate variability changes were induced by ajmaline in BrS patients, and increased microvolt T wave alternans (mTWA) was observed only in BrS patients. Patients with BrS who experienced ventricular arrhythmias during follow-up showed worse changes during ajmaline testing, including lower low frequency power and higher maximum mTWA.
CLINICAL AUTONOMIC RESEARCH
(2023)
Review
Oncology
Julia Katharina Schwarze, Xenia Geeraerts, Sandra Tuyaerts, Bart Neyns
Summary: This review highlights the unique role of dendritic cells (DCs) in cancer and discusses how specific subsets of DCs can be manipulated to induce an effective and durable antitumor response.
CURRENT OPINION IN ONCOLOGY
(2023)
Article
Neurosciences
B. Tassignon, A. Radwan, J. Blommaert, L. Stas, S. D. Allard, F. De Ridder, E. De Waele, L. C. Bulnes, N. Hoornaert, P. Lacor, E. Lathouwers, R. Mertens, M. Naeyaert, H. Raeymaekers, L. Seyler, A. M. Van Binst, L. Van Imschoot, L. Van Liedekerke, J. Van Schependom, P. Van Schuerbeek, M. Vandekerckhove, R. Meeusen, S. Sunaert, G. Nagels, J. De Mey, K. De Pauw
Summary: This study evaluated the whole-brain structural connectivity and cognitive performance of COVID-19 survivors through brain scans and cognitive tests. The results showed that the adverse effects of COVID-19 on brain functioning and structure decrease over time. However, future research with larger sample sizes, matched control groups, and longer follow-up periods is needed to confirm these findings.
EXPERIMENTAL BRAIN RESEARCH
(2023)
Review
Oncology
Wiebrecht Debel, Ali Ramadhan, Caroline Vanpeteghem, Ramses G. Forsyth
Summary: In recent years, there has been increasing scientific interest in the interaction between anaesthesia and cancer development. Retrospective studies have shown contradictory results regarding the influence of anaesthetics on cancer outcome and recurrence. However, recent scoping reviews have found that certain anaesthetics may have direct biological effects on cancer cells, but these effects are only significant in high concentration and long duration studies, which are not reflective of clinical use.
Article
Cardiac & Cardiovascular Systems
Luigi Pannone, Antonio Bisignani, Randy Osei, Anais Gauthey, Antonio Sorgente, Pasquale Vergara, Cinzia Monaco, Domenico Giovanni Della Rocca, Alvise Del Monte, Antanas Strazdas, Joerelle Mojica, Maysam Al Housari, Vincenzo Miraglia, Sahar Mouram, Gaetano Paparella, Robbert Ramak, Ingrid Overeinder, Gezim Bala, Alexandre Almorad, Erwin Stroker, Gudrun Pappaert, Juan Sieira, Thomy de Ravel, Mark La Meir, Pedro Brugada, Gian Battista Chierchia, Sonia Van Dooren, Carlo de Asmundis
Summary: The diagnostic yield of SCN5A gene testing in paediatric BrS patients is 46%, and having a P/LP variant in SCN5A is associated with a worse arrhythmic prognosis in children with BrS. There is no significant difference in the prognosis of ventricular arrhythmias between paediatric and adult BrS patients.
Review
Oncology
Iris Dirven, An-Sofie Vander Mijnsbrugge, Sacha Mignon, Jens Tijtgat, Nicolas Kint, Bart Neyns
Summary: Auto-immune hemolytic anemia (AIHA) and hemophagocytic lymphohistiocytosis (HLH) are rare immune-related adverse events (irAEs) after immune checkpoint inhibitor treatment. Treatment guidelines for these conditions are lacking. We present two cases of patients with chronic lymphocytic leukemia (CLL) who developed AIHA and HLH along with AIHA during treatment for metastatic melanoma with the PD-1 immune checkpoint blocking mAb nivolumab. Additionally, we review published cases of immune-related AIHA and HLH and their correlation with CLL.
Article
Oncology
Jens Tijtgat, Evan Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, Anne Marie Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, Bart Neyns
Summary: Focal radiation necrosis of the brain (fRNB) is a potential adverse event following stereotactic radiation therapy (SRT) or stereotactic radiosurgery (SRS), with higher incidence in cancer patients treated with immune checkpoint inhibitors. A low-dose regimen of bevacizumab (BEV) was found to be effective in improving clinical symptoms and reducing edema volume in fRNB patients, without significant adverse effects. This fixed low-dose BEV regimen may serve as a well-tolerated and cost-effective alternative treatment option for fRNB, warranting further investigation.
Article
Oncology
Evelynn Vergauwen, Ramses Forsyth, Alexander Vortmeyer, Sven Glaesker
Summary: VHL disease is a hereditary tumor syndrome that causes specific types of tumors in certain organs. By studying the expression of hemangioblastic proteins in VHL-related tumors, it was found that these tumors have a common embryonic origin, which may explain the specific distribution of VHL-associated tumors.
Meeting Abstract
Oncology
N. Vanlaer, I. Dirven, M. Vounckx, J. Tijtgat, M. Verhaert, S. Aspeslagh, L. Decoster, A. Rogiers, B. Neyns
ANNALS OF ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Stefaan Six, Peter Theuns, Pieter Libin, Ann Nowe, Luigi Pannone, Bart Bogaerts, Simon Jaxy, Catharina Olsen, Gudrun Pappaert, Isel Grau, Juan Sieira, Sonia Van Dooren, Esther Scheirlynck, Julie Nekkebroeck, Marina Mallefroy, Carlo de Asmundis, Johan Bilsen
Summary: This study aimed to assess the psychosocial outcomes of Brugada syndrome (BrS) patients and propose tailored psychosocial care. The results showed that BrS patients had higher levels of mental distress and a higher prevalence of Type D personality compared to the general population.
Article
Medicine, Research & Experimental
Paolo A. Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Leisha A. Emens, Robert L. Ferris, Silvia C. Formenti, Omid Hamid, Douglas B. Johnson, Tomas Kirchhoff, Christopher A. Klebanoff, Gregory B. Lesinski, Anne Monette, Bart Neyns, Kunle Odunsi, Chrystal M. Paulos, Daniel J. Powell Jr, Katayoun Rezvani, Brahm H. Segal, Nathan Singh, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov
Summary: The discovery and development of novel immunotherapy treatments have greatly improved patient outcomes in various types of cancer. However, not all patients respond to immunotherapy and acquired resistance remains a challenge. New approaches, such as adoptive cell transfer, therapeutic vaccines, and immune checkpoint inhibitors, have shown promise in patients with inadequate response to current treatments.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Elke Lathouwers, Ahmed Radwan, Jeroen Blommaert, Lara Stas, Bruno Tassignon, Sabine D. Allard, F. De Ridder, E. De Waele, N. Hoornaert, P. Lacor, R. Mertens, Maarten Naeyaert, Hubert Raeymaekers, Lucie Seyler, A. M. Vanbinst, Lien Van Liedekerke, Jeroen Van Schependom, Peter Van Schuerbeek, Steven Provyn, Bart Roelands, Marie Vandekerckhove, R. Meeusen, Stefan Sunaert, G. Nagels, J. De Mey, Kevin De Pauw
Summary: COVID-19 can have negative impacts on the quality of life and induce neurological sequelae. This study reveals differences in structural brain connectivity and cognitive performance between former hospitalised COVID-19 patients and healthy controls.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)